Cancer biomarker Market Research Report- Global Forecast till 2023

1. www.marketresearchfuture.com Cancer biomarker Market Research Report- Global Forecast till 2023 P a g e | 1 Copyright © 2017 Market Research Future.

2. www.marketresearchfuture.com Cancer is one of the leading causes of death across the globe. The early stage cancer is diagnosed with the help of biomarkers that are molecules, proteins, or processes indicating the presence of cancerous cells and biological state of tumors in the body. As per the report that has been published by Market Research Future (MRFR), the global cancer biomarkers market is anticipated to expand remarkably at a noteworthy CAGR of 15.8% during the forecast period of 2017-2023. The global cancer biomarker market is expected to grow at a CAGR of 15.8% during the forecast period, 2017-2023. cancer biomarker market is primarily driven by factors including adoption of western lifestyles in the developing regions, extensive research of cancer biomarkers, encouragement for biomarker development by FDA, improved precision and speed of diagnosis, high investment through government and private funds in cancer-related research, and development of highly specific drugs. Intended Audience      Pharmaceutical Companies Government and private research companies Research and Development (R&D) Companies Drug Manufacturers and Suppliers Medical Research Laboratories Major key players in the global cancer biomarkers market that are profiled in the report published by MRFR are F. Hoffmann-La Roche AG (Switzerland), Becton Dickinson (U.S.), Abbott Laboratories (U.S.), PerkinElmer, Inc. (U.S.), Bristol-Myers Squibb (U.S.), Bio-Rad Laboratories (U.S.), Eli Lilly and Company (U.S.), Merck & Co., Inc. (U.S.), Pfizer Inc. (U.S.), GlaxoSmithKline Plc. (U.S.), QIAGEN N.V (U.S.), Novartis AG (Switzerland), Thermo Fisher Scientific Inc. (U.S.), Illumina Inc. (U.S.) and others. Avail Sample Copy for This Report at: https://www.marketresearchfuture.com/sample_request/5378 The global population has witnessed an alarming surge in cancer, with about 14 million new cancer cases reported each year. According to WHO, it is anticipated to further increase over the next two decades by 70% with 22 million new cancer cases in 2012. The global cancer biomarker market is segmented on the basis of types, applications and end users.   On the basis of types, the market is segmented into protein biomarker, genetic biomarker and others On the basis of application, the market is segmented into diagnostic, prognostic and therapeutic. The diagnostic sub-segment is further classified into imaging and non- Imaging. On the basis of end users, the market is segmented into pharmaceutical and biotechnology companies, diagnostic tool companies, healthcare it/big data companies, clinical laboratories  Market Drivers and Restraints: Rise in prevalence of cancer and extensive research in biomarkers by various research institutes are some of the major factors driving the growth of the global cancer biomarkers market. Extensive application of cancer biomarkers for diagnosis and identification of early-stage cancer, risk assessment, prognosis and treatment predictions, monitoring treatment response and others are fueling the growth of the global cancer biomarkers market. The increasing use of biomarkers in cancer research for development of effective new drugs and increasing application of cancer biomarkers in the area of surrogate endpoints are positively impacting the growth of the global cancer biomarkers market. Proliferation in government initiatives and funding for development of novel cancer diagnostic techniques is acting as one of the major drivers for the expansion of the global cancer biomarkers market. P a g e | 2 Copyright © 2017 Market Research Future.

3. www.marketresearchfuture.com Increasing adoption of advanced technology for research and development of highly effective drugs and accurate diagnosis of cancer are anticipated to fuel the growth of the global cancer biomarkers market. However, high cost of development and validation of biomarkers, reluctance in adoption of advanced technology and low detection rate are likely to act as restraints on the growth of the global cancer biomarkers market. The global cancer biomarkers market is regionally segmented into North America, South America, Europe, Asia Pacific and the Middle East and Africa. Brows Detailed Report at: https://www.marketresearchfuture.com/reports/cancer-biomarker-market-5378 Cancer treatment is primarily responsible of health care costs in the world and thus is one of the key restraining factor in the global cancer biomarkers market. Many patients who are suffering from cancer cannot afford its treatment. Therefore, reimbursement issues and the need for immediate processing are restraining this market. Moreover, the success rate of clinical trials are low of biomarkers is the major factor hindering the cancer biomarker market. There are high investments and low benefit-cost ratio associated with the development of cancer biomarkers which is making it one of the major restraints of cancer biomarkers market. The market growth in this region can be attributed to the rising expenditure for the healthcare sector and improving healthcare infrastructure. Avail Discount Enquiry for this Report. About Market Research Future: MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions. Contact: Market Research Future +1 646 845 9312 Email: sales@marketresearchfuture.com P a g e | 3 Copyright © 2017 Market Research Future.

4. www.marketresearchfuture.com P a g e | 4 Copyright © 2017 Market Research Future.